{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:08:06Z","timestamp":1789380486806,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T00:00:00Z","timestamp":1106870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Although the dose of 400\u2003mg\/kg body weight intravenous immunoglobulins (IVIG) every 3\u20134\u2003weeks is now standard for treating patients with common variable immune deficiency, studies demonstrating its long\u2010term benefits over low 200\u2003mg\/kg dose and its effects on infectious subsets (upper\n                    <jats:italic>vs<\/jats:italic>\n                    lower respiratory\n                    <jats:italic>vs<\/jats:italic>\n                    non\u2010respiratory infections) are rare.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    All patients from a single center with the diagnosis of common variable immune deficiency and whose clinical chart was available during three successive therapeutic periods [a pre\u2010IVIG replacement period, a low\u2010dose (200\u2003mg\/kg every 3\u2003weeks) and a standard\u2010dose replacement period (400\u2003mg\/kg every 3\u2003weeks)] were screened retrospectively.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Seven patients followed up for a total of 116 patient\u2010years over the three defined periods of observation were recruited. When compared with low\u2010dose therapy, standard\u2010dose intravenous immunoglobulin therapy raised trough IgG levels from 4.3 to 6.5\u2003g\/l and significantly decreased the overall frequency of infections, with marked effects on lower respiratory tract and severe infection number. In contrast, non\u2010respiratory and upper respiratory infections were, in comparison, resistant to therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    Overall, these data support the use of standard\u2010dose 400\u2003mg\/kg intravenous immunoglobulin therapy, despite the high cost, to raise trough IgG levels to 5\u20137\u2003g\/l, but underlines that some categories of infectious events (non\u2010respiratory, upper respiratory) may need parallel surgical or pharmacological approaches to be optimally prevented or treated.\n                  <\/jats:p>","DOI":"10.1111\/j.1398-9995.2005.00756.x","type":"journal-article","created":{"date-parts":[[2005,1,29]],"date-time":"2005-01-29T05:01:29Z","timestamp":1106974889000},"page":"385-390","source":"Crossref","is-referenced-by-count":32,"title":["Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non\u2010respiratory infections in common variable immune deficiency"],"prefix":"10.1111","volume":"60","author":[{"given":"O.","family":"Favre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leimgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nicole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Spertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,28]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01117.x"},{"key":"e_1_2_10_3_2","first-page":"1","article-title":"Accessory and T cell defects in acquired and inherited hypogammaglobulinaemia","volume":"78","author":"Rozynska KE","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_10_4_2","first-page":"36","article-title":"Abnormal B cell response of protein kinase C in some common variable immunodeficiency","volume":"13","author":"Kaneko H","year":"1996","journal-title":"Exp Clin Immunogenet"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.d01-795.x"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1991.tb05704.x"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06228.x"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb02281.x"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni902"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61176-8"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(91)90306-9"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107113250207"},{"issue":"1","key":"e_1_2_10_13_2","first-page":"11","article-title":"Intravenous immune globulin in primary immunodeficiency","volume":"97","author":"Haeney M.","year":"1994","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"e_1_2_10_14_2","first-page":"1","article-title":"Primary immunodeficiency diseases. Report of an IUIS Scientific Committee","volume":"118","author":"International Union of Immunological Societies","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)90494-6"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90324-3"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01486738"},{"key":"e_1_2_10_18_2","first-page":"335","article-title":"High\u2010 vs low\u2010dose immunoglobulin therapy in the long\u2010term treatment of X\u2010linked agammaglobulinemia","volume":"146","author":"Liese JG","year":"1992","journal-title":"Am J Dis Child"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-3-200108070-00008"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2005.00756.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2005.00756.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T01:27:34Z","timestamp":1696901254000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2005.00756.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,28]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1398-9995.2005.00756.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2005.00756.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,28]]}}}